¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cytoplasmic polyhedrosis virus group"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • enveloped virus
    ²®Áúº¸À¯¹ÙÀÌ·¯½º, ¿ÜÇǺ¸À¯¹ÙÀÌ·¯½º
  • epidemic gastroenteritis virus
    À¯ÇàÀ§Àå¿°¹ÙÀÌ·¯½º
  • Epstein-Barr virus
    ¿¦½ºÅ¸ÀÎ-¹Ù¹ÙÀÌ·¯½º
  • foamy virus
    °ÅǰÇü¼º¹ÙÀÌ·¯½º
  • helper virus
    º¸Á¶¹ÙÀÌ·¯½º
  • hemadsorption virus
    Ç÷±¸ÈíÂø¹ÙÀÌ·¯½º
  • hepatitis E virus
    EÇü°£¿°¹ÙÀÌ·¯½º
  • hepatitis G virus
    GÇü°£¿°¹ÙÀÌ·¯½º
  • herpes simplex virus
    ´Ü¼øÇ츣Æä½º¹ÙÀÌ·¯½º
  • human immunodeficiency virus
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • human immunodeficiency virus-2
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º2
  • human papilloma virus
    »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º
  • human papilloma virus test
    »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º°Ë»ç
  • human T-cell lymphoma/leukemic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁÁ¾/¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T-cell lymphotropic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁģȭ¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • determinant group
    °áÁ¤±º
  • diagnosis related group
    À¯»çÁø´Ü±ºÀÇ·áºñÁöºÒ¹ý
  • didactic group therapy
    ±³À°Áý´Ü¿ä¹ý
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • group dynamics
    Áý´Ü¿ªÇÐ, Áý´Ü¿ªµ¿
  • end group
    ¸»´Ü±â
  • end group spine
    ±ê³¡°¡½Ã
  • enteric group
    âÀÚ±Õ±º
  • evocative group therapy
    Ç¥ÇöÁý´Ü¿ä¹ý
  • functional group
    ÀÛ¿ë±â
  • group
    ¹«¸®, ±º, Áý´Ü
  • group-specific
    ±ºÆ¯ÀÌ-
  • glucophore group
    ´ã´ç±â
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù
  • group hospital
    º´¿øÁ¶ÇÕ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • haptenic group
    ÇÕÅÙ±â(¡­Ðñ).
  • hearing aid, group
    Áý´Üº¸Ã»±â
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(¡­Ðñ).
  • incompatibility group, plasmid
    ÇÃ¶ó½º¹Ìµå ºñÀûÇÕ±º
  • indeterminate group
    ¹ÌÁ¤Çü±º(Ú±ïÒúþÏØ).
  • indeterminate group
    ¹ÌÁ¤Çü±º(ËÑËøÌ´Ë´).
  • posterior group of aphasia
    ÈĺνǾ(ý­Ý»ã÷åÞÏØ).
  • posterior group of aphasia
    ÈĺνǾ(ý­Ý»ã÷åÞÏØ)
  • prepaid group practice
    ¼±ºÒÁ¦Áý´Ü°³¿ø.
  • prostheitc group
    ¹èÇÕ±º(ÛÕùêÏØ).
  • prosthetic group-labeled enzyme
    º¸Á¶±ºÇ¥ÁöÈ¿¼Ò
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªÃøÁ¤(¹ý)
  • psittacosis-lymphogranuloma-trachoma (PLT) group
    PLT±º Ŭ¶ó¹Ìµð¾Æ
  • psittacosis-lymphogranuloma-trachoma group
    ¾Þ¹«(»õ)º´ ¸²ÇÁÀ°¾ÆÁ¾Áõ Æ®¶óÄÚ¸¶±º(¡­ë¿ä´ðþñø¡­ÏØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù.
  • group
    ±º
  • group I fiber
    Á¦¥°±º¼¶À¯(ð¯ìéÏØàéë«).
  • group I fiber
    Á¦¥°¤Çí·A(ð¯ìéÏØàéë«).
  • group II fiber
    Á¦¥± ±º¼¶À¯(ÏØàéë«).
  • group II fiber
    Á¦¥±¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • group IV fiber
    Á¦¥³±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • carbonyl group
    Ä«¸£º¸´Ò±â(Ðñ)
  • carboxyl group
    Ä«¸£º¹½Ç±â(Ðñ)
  • complementation group
    »óº¸±º(ßÓÜÍÏØ)
  • critical group
    ÀӰ豺(×üÍ£ÏØ)
  • diazo group
    µð¾ÆÁ¶ ±â(Ðñ)
  • diazonium group
    µð¾ÆÁ¶´½ ±â(Ðñ)
  • earthy group
    Å伺±â(÷ÏàõÐñ)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fatty acyl group
    Áö¹æ(ò·Û¸) ¾Æ½Ç±â(Ðñ)
  • fidelity group
    Á¤È®µµ ±â(ïáü¬ÓøÐñ)
  • formimino group
    Æ÷¸§À̹̳ë±â(Ðñ)
  • formyl group
    Æ÷¸£¹Ð±â(Ðñ)
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
  • functional group isomer
    ÀÛ¿ë±â(íÂéÄÐñ) À̼ºÃ¼(ì¶àõô÷)
  • glucosyl group
    ±Û·çÄڽDZâ(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ECI electrocerebral inactivity; eosinophilic cytoplasmic inclusions; extracorporeal irradiation
FCD feces collection device; fibrocystic disease; fibrocystic dysplasia; focal cytoplasmic degradation
MCB membranous cytoplasmic body
N:C nuclear-cytoplasmic ratio
NCR National Research Council; neutrophil chemotactic response; no carbon required; nuclear/cytoplasmic ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
group II group I
Group III group
ANCA Anti-Neutrophil Cytoplasmic Antibodies
ANCA Anti-Neutrophil Cytoplasmic Antibody
ANCAs Anti-neutrophil cytoplasmic antibodies
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • infectious hepatitis virus
    Àü¿°¼º °£¿° ¹ÙÀÌ·¯½º
  • Japanese encephalitis virus
    ÀϺ» ³ú¿° ¹ÙÀÌ·¯½º
    ÀϺ» ³ú¿°ÀÇ º´¿øÃ¼. 1934³â¿¡ ÇϾ߽ð¡ ³ú³» Á¢Á¾¹ý¿¡ ÀÇÇØ óÀ½ ¿ø¼þÀÌ¿¡°Ô ÀüÆÄÇϰí, 36³â¿¡´Â ´Ù´Ï±¸Ä¡, °¡»çÇ϶ó µîÀÌ ½ÇÇè¿ë Á㸦 ÀÌ¿ëÇÏ¿© ºÐ¸®¿¡ ¼º°øÇÏ¿´´Ù. Å©±â´Â 15¡­30 mÀÌ°í ¼¼ÀÎÆ®·çÀ̽º ³ú¿°À̳ª ¼­ ³ªÀÏ ³ú¿°ÀÇ ¹ÙÀÌ·¯½º¿Í ºñ½ÁÇѵ¥, º´µ¶ÀÇ ÁßÈ­ ½ÃÇèÀ¸·Î ±¸º°ÇÑ´Ù. ¸ð±â°¡ ¸Å°³ÇÏ¿© »ç¶÷°ú °¡Ãà¿¡ °¨¿°µÇ´Âµ¥, ¸ð±â°¡ ¾ø´Â µ¿°è¸¦ ¾î¶»°Ô ³Ñ±â°í ´ÙÀ½ÇØ¿¡ ´Ù½Ã À¯ÇàÇÏ´ÂÁö ÆÇ¸íµÇ¸é ¿¹¹æ ´ëÃ¥ÀÌ È®¸³µÇ´Â °ÍÀ̳ª ¾ÆÁ÷ ¹àÇôÁöÁö ¾Ê°í ÀÖ´Ù. ¿Â´ëÁö¹æ¿¡¼­´Â µ¿¸éÇÑ ¸ð±âÀÇ Ã¼³»¿¡¼­ ÇØ¸¦ ³Ñ±æ °¡´É¼ºµµ ÀÖÀ¸³ª ¾ÆÁ÷ ÀÔÁõµÇÁö ¾Ê¾Ò°í, ¸ð±â¸¦ Àâ¾Æ¸Ô´Â µµ¸¶¹ìÀ̳ª µµ¸¶¹ìºÙÀÌÀÇ Ã¼³»¿¡¼­ ÇØ¸¦ ³Ñ±æ °¡´É¼ºÀ̳ª, µÕÁö¸¦ ¶°³¯ ¼ö ¾ø´Â µé»õ, ƯÈ÷ ±îÄ¡·ùÀÇ Ã¼³»¿¡¼­ »ì¾Æ³²´Â´Ù´Â °ßÇØµµ ÀÖ´Ù. ÇÑÆí °¨¿°µÈ ¸»À̳ª µÅÁö´Â ±× ÇØÀÇ ¹ÙÀÌ·¯½º¸¦ ¼ºÀå½Ãų ¼ö´Â ÀÖÀ¸³ª ¹ÙÀÌ·¯½ºÀÇ º¸À¯ µ¿¹°Àº ¾Æ´Ï¶ó°í ÇÑ´Ù.
  • Lassa fever virus
    ¶ó»ç ¿­ ¹ÙÀÌ·¯½º
    ¾Æ·¹³ª ¹ÙÀÌ·¯½º°ú¿¡ ¼ÓÇÏ¸ç ¼­¾ÆÇÁ¸®Ä«¿¡ »ç´Â ¾ÆÇÁ¸®Ä« ÁýÁã »çÀÌ¿¡ Áö¼Ó °¨¿°µÇ°í ÀÖÀ¸¸ç »ç¶÷¿¡ ´ëÇÑ °¨¿°Àº Ÿ¾×À̳ª ´¢Áß¿¡ ¹è¼³µÈ ¹ÙÀÌ·¯½º¿¡ ¿À¿°µÈ À½½Ä¹°À̳ª ½Ä±â¸¦ ÅëÇØ¼­ ÀϾ´Ù.
  • lymphadenopathy virus
    ¸²ÇÁÀýÁõ ¹ÙÀÌ·¯½º
  • lymphocystis virus
    ÀÓÆÄ ³¶Á¾ ¹ÙÀÌ·¯½º
  • measles virus
    È«¿ª ¹ÙÀÌ·¯½º
    ÆÄ¶ó ¹Í¼Ò ¹ÙÀÌ·¯½ºÀÇ ÀϹÝÀû ¼º»óÀ» Áö´Ñ º´¿øÃ¼·Î, »ç¶÷°ú ¿ø¼þÀÌ¿¡ º´¿ø¼ºÀ» ³ªÅ¸³½´Ù. RNA ¹ÙÀÌ·¯½º·Î 56¡É¿¡¼­ 30ºÐ °¡¿­ÇÏ¸é ºÒȰ¼ºÈ­µÈ´Ù. È«¿ª ȯÀÚÀÇ Ä§, °¡·¡, ¿ÀÁÜ¿¡ ÀÖ´Ù. È«¿ª ¹ÙÀÌ·¯½º°¡ Á¸ÀçÇÏ¸é ¸²ÇÁ±¸ Áõ°¡¿Í ¹éÇ÷±¸ °¨¼Ò°¡ º¸ÀÌ°í ¸²ÇÁÀý, Æíµµ¼± µî¿¡´Â ´ÙÇÙ ¼¼Æ÷°¡ ³ªÅ¸³­´Ù
  • monkey pox virus
    ¿ø¼þÀÌ Æø½º ¹ÙÀÌ·¯½º
  • neonatal calf diarrhea corona virus
    ½Å»ý¾Æ ¼³»ç Äڷγª ¹ÙÀÌ·¯½º
  • neurotropic virus
    Çâ½Å°æ¼º ¹ÙÀÌ·¯½º
  • oral herpes simplex virus
    ±¸°­ ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º
  • papilloma virus
    À¯µÎÁ¾ ¹ÙÀÌ·¯½º
    Àΰ£°ú µ¿¹°¿¡¼­ À¯µÎÁ¾ ¶Ç´Â »ç¸¶±Í¸¦ ÀÏÀ¸Å°´Â ¹ÙÀÌ·¯½ºÀÇ ¹«¸®. ÆÄº¸¹Ù ¹ÙÀÌ·¯½º°ú¿¡ ¼ÓÇÑ´Ù. º´ÀÇ ÀüÆÄ´Â º¸Åë ȯÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃËÀ̳ª ÀÚ°¡ Á¢Á¾¿¡ ÀÇÇÑ´Ù. »ç¸¶±Í´Â ÀϹÝÀûÀ¸·Î ÀÚÀ²¼º º´º¯À¸·Î 6°³¿ù ³»Áö 2³â ³»¿¡ ÀÚ¿¬ ¼Ò½ÇµÈ´Ù.
  • parainfluenza 1 virus
    Á¦1Çü ÆÄ¶ó ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º
  • parainfluenza 3 virus
    Á¦3Çü ÆÄ¶ó ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
group I mycobacteria Mycobacteria that produce a bright yellow colour when grown in the presence of light. Organisms placed in this group appear to belong to the species Mycobacterium kansasii.
Synonym: photochromogens.
(05 Mar 2000)
group IV mycobacteria Mycobacteria that grow rapidly and that do not produce pigment. Organisms placed in this group belong to such species as Mycobacterium ulcerans and M. Marinum.
(05 Mar 2000)
group practice Any group of three or more full-time physicians organised in a legally recognised entity for the provision of health care services, sharing space, equipment, personnel and records for both patient care and business management, and who have a predetermined arrangement for the distribution of income.
(12 Dec 1998)
group practice, dental Any group of three or more full-time dentists, organised in a legally recognised entity for the provision of dental care, sharing space, equipment, personnel and records for both patient care and business management, and who have a predetermined arrangement for the distribution of income.
(12 Dec 1998)
group practice, prepaid An organised group of three or more full-time physicians rendering services for a fixed prepayment.
(12 Dec 1998)
group processes The procedures through which a group approaches, attacks, and solves a common problem.
(12 Dec 1998)
group psychotherapy A type of psychological treatment involving several patients participating together in the presence of one or more psychotherapists who facilitate both emotional and rational cognitive interaction to effect uniquely targeted changes in the maladaptive behaviour of the individual patient in his or her everyday interpersonal exchanges. See also entries under group.
(05 Mar 2000)
group purchasing A shared service which combines the purchasing power of individual organizations or facilities in order to obtain lower prices for equipment and supplies.
(12 Dec 1998)
group reaction A reaction with an agglutinin or other antibody that is common (though usually in varying concentrations) to an entire group of related bacteria, e.g., the coli group.
(05 Mar 2000)
group-specific protease <enzyme> A serine protease, obtained from rat small intestine, which preferentially inactivates the apo forms of certain pyridoxal phosphate requiring enzymes
Registry number: EC 3.4.21.-
(26 Jun 1999)
group structure The informal or formal organization of a group of people based on a network of personal relationships which is influenced by the size and composition, etc., of the group.
(12 Dec 1998)
group test In psychology, a test designed to be administered to more than one individual at a time; e.g., scholastic achievement test, medical college admissions test.
(05 Mar 2000)
group transfer The transfer of a functional moiety from one molecule to another.
(05 Mar 2000)
group translocation A process of actively importing compounds into the bacterial cell. The compound diffuses into the cell passively, and is immediately modified (for example by phosphorylation) so that it cannot diffuse back out.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á